prostate cancer

[Ecotoxicology and Environmental Safety] Colony formation assay showed that the cells with AR, mTOR and DDIT3 knockdown could remarkably mitigate the cell proliferation ability in both PC-3 and LNCap cells.

[Noxopharm Limited (BusinessWire, Inc.)] Noxopharm Limited has reported pre-clinical data confirming a survival benefit of adding Veyonda® to 177lutetium-PSMA-617 treatment in prostate cancer.

[Medical Oncology] Researchers verified the resistance levels of parental and resistant PC3 prostate cancer cells to bortezomib using WST-1 test.

[Journal of Materials Chemistry B] Researchers successfully developed active targeted upconversion nanoparticles as potential probes for dual near-infrared–near-infrared fluorescence and radioactive-guided surgery of prostate-specific membrane antigen prostate cancers.

[Lasers in Medical Science] Scientists determined the effect of conjugated cisplatin and low-level laser treatment on the viability of LNCaP prostate cancer cell line. LNCaP cells were harvested in DMEM containing 10% FBS and 1% antibiotic.

[Scientific Reports] Researchers used flow cytometric analysis, cell viability assay, caspase activity analysis, wound healing assay, confocal microscopy study, and immunofluorescence to investigate the biological effect of high-frequency nanosecond pulses electric fields on prostate cancer cells.